BioAdaptives, Inc. (OTC: BDPT) has announced the commercial launch of XcellaraHeart, a cardiovascular wellness supplement scheduled to be available for order on Aug. 1, 2026, with initial deliveries expected in early August. The product combines the company’s Xcellara stem/progenitor cell mobilization formula with Tanshinone IIA, a bioactive compound derived from Danshen root, aiming to support cardiovascular health through a two-part strategy.
The Xcellara base formula is supported by a randomized, double-blind, placebo-controlled clinical trial that demonstrated an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks, with zero adverse effects on more than twenty blood parameters. This data, according to the company, provides a foundation for the new supplement. Tanshinone IIA has been studied for its effects on the SDF-1α/CXCR4 signaling pathway, which is associated with cellular trafficking and cardiovascular repair biology.
For business leaders and technology watchers, this announcement signals a potential shift in the nutraceutical industry toward evidence-based formulations backed by rigorous clinical trials. The use of a double-blind, placebo-controlled study is rare in the dietary supplement space, and the reported 268.8% increase in stem/progenitor cells could have significant implications for cardiovascular wellness if replicated in broader populations. The product’s focus on cellular mobilization and signaling pathways aligns with emerging trends in regenerative medicine and personalized health.
BioAdaptives has made a scientific evidence dossier detailing the formulation available on the company’s product website at products.xcellara.com/science. The dossier separates what has been demonstrated in BioAdaptives’ human clinical research on the Xcellara base from published research on Tanshinone IIA and from the company’s product-development rationale for combining the two. This transparency may appeal to consumers and investors seeking verifiable claims.
The Xcellara product line includes seven targeted formulas that combine the clinically proven mobilization base with tissue-specific signaling ingredients for cardiac, joint, neural, dermal, longevity, and stress-resilience applications. XcellaraHeart represents the cardiac-focused entry in this lineup. The company’s flagship Xcellara base formula is described as the only dietary supplement with a human randomized, double-blind, placebo-controlled clinical trial demonstrating such an increase in hematopoietic stem and progenitor cells.
For the industry, this launch could set a new standard for clinical validation in the supplement market. If the product gains traction, competitors may need to invest in similar trials to substantiate their claims. For consumers, access to a supplement with peer-reviewed clinical data may provide greater confidence in its efficacy. However, it is important to note that the trial data pertains to the Xcellara base alone, not the combined XcellaraHeart formulation, and the company’s rationale for the combination is based on published research on Tanshinone IIA.
BioAdaptives is the developer of the Xcellara line of stem cell mobilization and tissue-homing supplements. More information is available at www.bioadaptives.com. The full press release is available at https://nnw.fm/G14S7.
